论文部分内容阅读
几年来国营医药工业产品的品种有显著的增加,过去有些一向依靠国外进口的药品和医药器械,我们都已先后试制成功,并进行了大规模生产。产品质量方面也有不少改进与提高,因此,返工率减少,废品率降低。如盐酸氯胍、盐酸麻黄素、磺胺噻唑、磺胺胍和氯微素等产品的纯度融点都已达到或超过了“中国药典”(1955年版)规定的标准;新华制药厂20毫升葡萄糖针剂的废品率最低达到1.5%,东北制药厂葡萄糖返工率亦比1952年减少了一半。这些成绩都是全体(?)工努力的结果。
In the past few years, the varieties of state-owned pharmaceutical industrial products have markedly increased. In the past, some pharmaceuticals and medical equipment that had always been imported from abroad were successfully trial-produced and mass-produced. Product quality also has a lot of improvement and improvement, therefore, reduce the rework rate, reduce the rejection rate. Such as proguanil hydrochlorid, ephedrine hydrochloride, sulfathiazole, sulfadiazine, chlorin and other products have reached or exceeded the purity of the melting point “Chinese Pharmacopoeia ” (1955 edition) the standard; Xinhua Pharmaceutical Factory 20 ml glucose injection The lowest scrap rate reached 1.5%, northeast pharmaceutical factory glucose rework rate is also reduced by half compared with 1952. These results are the result of all the hard work.